MESO
HEALTHCAREMesoblast Ltd
$15.81+0.02 (+0.13%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MESO Today?
No stock-specific AI insight has been generated for MESO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$9.88$21.50
$15.81
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-0.75
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-1.4%
Debt / Equity—
Trading
Volume221K
Avg Volume (10D)—
Shares Outstanding129.3M
MESO News
20 articles- How Completion Of RMAT Phase 3 Enrollment At Mesoblast (ASX:MSB) Has Changed Its Investment StoryYahoo Finance·May 1, 2026
- Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 MillionGlobeNewswire Inc.·Apr 30, 2026
- ASX Penny Stocks To Watch In April 2026Yahoo Finance·Apr 29, 2026
- ASX Growth Companies With High Insider Ownership In April 2026Yahoo Finance·Apr 29, 2026
- Assessing Mesoblast’s Valuation After Recent Share Price Weakness And Conflicting Growth SignalsYahoo Finance·Apr 29, 2026
- Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back PainGlobeNewswire Inc.·Apr 29, 2026
- Mesoblast Ltd (MESO): Secure Exclusive Rights to a Vital PlatformYahoo Finance·Apr 28, 2026
- Why Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest inYahoo Finance·Apr 20, 2026
- Mesoblast Limited (MESO), One of the Best Long-Term ASX Stocks To Buy Right Now; See WhyYahoo Finance·Apr 19, 2026
- Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell ProductsYahoo Finance·Apr 15, 2026
- Gregory George Adds To Mesoblast Position With Multi-Market Share PurchasesYahoo Finance·Apr 12, 2026
- Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTIONYahoo Finance·Apr 10, 2026
- Mesoblast (ASX:MSB) Is Down 11.0% After FDA Clears Registrational DMD Trial For Ryoncil - Has The Bull Case Changed?Yahoo Finance·Apr 9, 2026
- Mesoblast R&D Day: Ryonsel Gains Traction, Back Pain Phase III Nears Finish, New Shots on GoalMarketbeat·Apr 8, 2026
- Is Mesoblast (ASX:MSB) Price Swings Creating A Possible Valuation Opportunity?Yahoo Finance·Apr 8, 2026
- Mesoblast R&D Day Features Significant Commercial Progress & Platform InnovationYahoo Finance·Apr 8, 2026
- Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular DystrophyGlobeNewswire Inc.·Apr 8, 2026
- Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March QuarterGlobeNewswire Inc.·Apr 7, 2026
- Mesoblast to Host R&D Day on April 8, 2026Yahoo Finance·Mar 17, 2026
- Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at MesoblastYahoo Finance·Mar 11, 2026
All 20 articles loaded
Price Data
Open$15.71
Previous Close$15.79
Day High$16.06
Day Low$15.62
52 Week High$21.50
52 Week Low$9.88
52-Week Range
$9.88$21.50
$15.81
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-0.75
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-1.4%
Debt / Equity—
Trading
Volume221K
Avg Volume (10D)—
Shares Outstanding129.3M
About Mesoblast Ltd
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—